Lincoln Financial Group, LNC: Radnor, Pennsylvania, United States

Why should we choose Lincoln Financial Group over another financial institution and does the Lincoln Financial Group offer the customer anything different from the other players in the market place.

Let us face it, ten years ago and further back the financial institutions were having a field day with unsuspecting clients, and acting recklessly in their activities.

When the crash of 2008 came along, there were heads to roll and the day of reckoning had come for many of these unscrupulous financial investment companies and their CEO’S.

Leap forward ten years and now there are multiple financial regulatory bodies to keep us, the customer safe from frowned upon practices.

So what is the Lincoln Financial Group?

Lincoln Financial Group is a group of companies and subsidiaries such as Transamerica all operating under the umbrella of AEGON.

There are some 30 subsidiaries within the group all offering overlapping products that compliment its sister companies offerings of products.

By taking, this approach in the financial services market Lincoln Financial Group can leverage a greater market share along with the other subsidiaries by offering complete financial solutions to the financial services market.

Lincoln Financial Group is the marketing name for Lincoln National Corporation (NYSE:LNC) and its affiliates.

Who owns the Lincoln Finance Group?

Lincoln Finance Group is owned by the parent company Lincoln National Group. This is a national corporation and listed as a fortune 250 companies. Lincoln National Group operates its financial services such as annuities and insurance through Lincoln Finance Group.

What products does the Lincoln Financial Group offer?

Like most financial service companies, Lincoln offers the same products as many of the others such as:

Retirement plans Annuities
Education plans
Life insurance
Protected income plans
Financial legacy plans
Fixed and variable annuity plans

These are just a few of the services offered by Lincoln Finance Group.

Who are the group executives of the Lincoln Financial Group?

Name	Position
Dennis R. Glass	CEO & President
Dick Mucci	Executive VP
Gary C. Kelly	CEO Southwest Airlines
Ellen Cooper	Chief investment officer
Deirdre Connelly	Director
Isaiah Tidwell	Director
William H. Fuller	President annuity solutions
Lyn M. Utter	CEO First source

As you can see the executive, team is a of a diverse group of executives each bringing industry knowledge making the Lincoln Finance Group experts in the industry and providing its clients with the correct solution to their financial needs.

Where can I find the Lincoln Finance Groups Headquarters?

Lincoln Finance group has it’s headquarter located in 150 N Radnor Chester RD Radnor 19087-5252 United States USA.
You can call Lincoln Finance Group phone number toll free 800-487-1485
Alternatively, you can email custservteam@lfg.com

Official Website Company directory Bloomberg

What year was Lincoln Group created?

Lincoln was created in 1905 in Fort Wayne Indiana. The company name is taken from the family name of Abraham Lincoln, which was thought to represent trust and integrity.

The name was actually authorized for use by Abraham Lincoln and a letter delivered by his son Todd Lincoln and confirmed the company could use the facial image of the president as there logo.

Lincoln Finance Group holds a patent for insurance! Yes, you read that correct they hold a patent for insurance. The patent covers variable annuities and is still in use today to calculate variable annuity end of term payments.

Is there a Lincoln Finance group representative or office near me?

Lincoln Finance Group operates throughout the country with multiple offices and hundreds of financial advisors across the US.

Where can I find a Lincoln financial advisor?

In the first instance, you can check the official website www.lfg.com where you will find many options for locating a financial advisor. This is the best option for most clients because you can choose which product you wish to purchase and discuss further and be directed to financial professional who can assist you with your inquiry.

How can I withdraw money from Lincoln Financial Group?

This should be straightforward and easy to get it started but in some cases, it is more complex than one would think. This is because when you initiate a life policy or annuity there is invariably a term to the policy.

Having a term to the policy is easy to understand. When your policy comes into force, it is normal that there will be a fixed maturity period of say 15 years.

If you decide to withdraw from the policy before the 15-year maturity when your policy has not reached its full earnings potential and the company will lose money.

This is why there are always penalties for withdrawing money early from a non-matured policy.
However, if your policy is well on its way to maturity it is possible to take a policy loan. This can be done in two stages, USD 50,000 and 50,000 and above.

For the first option, you will need to contact customer service and discuss your requirements where the customer service representatives will help you further to release money from your policy.

For the second option of 50,000 + you will need to fax or mail the customer service department stating your request with your complete details like SSN, Tax ID, policy number and date of inception.

Never ever, give usernames and passwords when using fax transmissions or when sending requests through post.
Taking a low interest loan from your annuity or insurance policy may seem like a great idea knowing you can repay the loan through salary deductions over a period.

It can be a great idea however; there are pitfalls you should understand.
Removing funds from an active policy will inevitably cost you in the end. You will be paying administration fees from the very moment you start the process.

You can potentially miss bonus payments that could be significant depending on the value of your policy.
I would always advise trying to find another option for funding before touching your policy.

Conclusion

Lincoln Finance Group can offer you sound investment plans which is backed by multi-billion dollar assets for you peace of mind and security.

Lincoln Finance is a good choice for planning your finances into the future.

As with most financial services companies Lincoln Finance Group offer great careers and are always looking to extend their talent pool. Contact Human Resource for further information through the official website should you be interested in a new career.

Transamerica Corporation Headquarters: Cedar Rapids, Iowa, United States

In this article, I will discuss the Transamerica Corporation and offer the readers a brief insight into the Transamerica Corporation and some of its many subsidiaries.

I will let you know what the Transamerica Corporation offers its clients and if this is the company for you and your future investments.

Who is Transamerica Corporation?

In terms of longevity and security, you can have confidence that the Transamerica Corporation is a well-established player in the financial industry and have been around a long time.

Transamerica Corporation came into existence in 1904 and its original founder was Amadeo Giannini. Amadeo Giannini had the vision to create financial services accessible to everyone.

Today the President and CEO Mark W. Mullin who has been at the helm for the past eight years and nine months, he is a stalwart of the financial industry.

The senior executives of Transamerica are listed below:

Mark William Mullin	Chief Executive officer
Blake Steven Bostwick	Executive VP & COO
James Martin Flewellen	President Transamerica Insurance
Michael F. Cosendine	Senior VP Government Affairs
David Roy MacMillan	Chief Customer Experience Officer

Transamerica Corporation has its headquarters in Cedar Rapids, Iowa, United States. Its official website is www.transamerica.com and the Telephone # 1-800 Pyramid.

Transamerica Corporation have two thousand five hundred employees across the globe and has some thirty subsidiaries including household names such as World Financial Group and Lincoln Financial, to mention a few.

Transamerica List of products and services

As one would expect from an established financial service provider such as Transamerica Corporation the company offers a portfolio of products to suit the inclusive financial needs for all working persons in today’s society.

Transamerica Corporation offers.

Retirement financial options
Mutual Funds
Annuities
Insurance services
Employee benefit packages
Exchange traded Funds
Medicare

Along with these products, there are a number of services one would expect like a taxation center, financial education knowledge place and more.

Millennial’s in the United States are particularly interested in investing for the future and retirement. The Transamerica Corporation and its subsidiaries offer the perfect platform for your 401K should your employer not offer this service to you.

Transamerica Corporation offers legitimate financial services including quotes for life insurance and even loan processing should you be considering a loan as a financial option into today’s burgeoning stock market.
Some of the best life insurance is through Transamerica and its subsidiaries, Transamerica and its subsidiaries are in office locations near to you.

San_Francisco_harbor_scene_with_Transamerica_Pyramid.png — The building no longer houses the headquarters of the Transamerica Corporation

Contacting Transamerica

Transamerica Corporation has made contacting the company simple; you can create an account and login at your convenience at any time.

To create an account is as simple as clicking support on the web page header. Select the product or products you are interested in and register your account.

As with all websites, you will have a unique user name and password.

If you have forgotten your password, do not worry. Just follow the simple steps provided on the login page and you will receive a password reset.

Before you get to the password reset, you will need to submit your SSN or Tax ID to verify your identity. Once done it is plain sailing.

FAQ’s

How long has Transamerica been in Business?

Transamerica has been in business for 114 years.

When was the Transamerica founded?

Transamerica was founded back in 1904 in San Francisco. Interestingly, the iconic Transamerica logo is from their pyramid building that dominated the skyline of San Francisco for many years. However, it is no longer the corporate headquarters.

Can I cancel my life insurance policy?

Yes, you can cancel your life insurance policy. However, as with industry standards life insurance policies normally have a fixed term. The Transamerica life insurance policy has a term of fifteen years that means if you are under the fifteen year fixed term you will be penalized for surrendering the policy.

Before you take this route, ask yourself why you want to surrender the policy and is there a better option for you.
Many leading insurance companies recognize that over time some products no longer suit the needs of the customer and will offer a different policy if you are prepared to transfer.

Another option is to speak with your financial advisor about the possibility of selling your policy. There are companies in the market who will buy certain financial products and wait for the product to mature.

Invariably, there will be a fee for transferring your policy. This will be your best option. If you are certain your current policy no longer meets your needs.

If you want to withdraw completely Transamerica Corporation will oblige without hassle.

Can I pay my monthly premium online?

You have the option to pay your premiums through direct debit from your bank account. However, the simplest way is to use Western Union speed pay, which can be completed online from any location.

Contacting Transamerica.

Contacting Transamerica Corporation could not be simpler, you can contact via the official website or the telephone numbers posted online.

Here is some useful information should you need to contact Transamerica Corporation.
Policy Holders and General Information
Tel 800-797- 2643 Monday to Friday 9am-6pm ET
Tii.customerservices@transamerica.com
Need a Quote
Tel 855-288-4181 Monday-Friday 9am-5PM
Website Support
Tel 877-717-8858
www.webhelp@transamerica.com

Transamerica Medicare supplements claims.

Tell toll free 800-229-6565
Address 100 Light St, FL B1, MS 3239
Baltimore, MD 21202-2559
Please be aware when contacting Transamerica via email do not give website user name or passwords for your security.

Summary

I could only find positive reviews with regard to Transamerica except for a lawsuit for a patent infringement.
If you are looking to the future and have decided that now is the time to invest in your 401K, or an annuity or other policy that meets your needs, then Transamerica Corporation will be able to offer you competitive products within the market place.

With a broad range of subsidiaries you will find Transamerica Corporation have all of your needs covered.
Financial advisors and products are tightly regulated which should give you the confidence to proceed with your investments without fear or trepidation. There is no better time than now to take the opportunity to invest in your future with Transamerica Corporation.

Transamerica are always hiring talented people from diverse backgrounds, should you be interested in applying for a position contact Human Resources through the website.

Footnote

Please do not confuse Transamerica with Trans American auto parts.

BCR (NYSE): C. R. Bard, Inc. Headquarters

Pharmaceutical and healthcare companies are highly dedicated in giving the utmost service and product pipelines to its ventures. These companies are merged together in order to deliver the demands. Mentioning one of the key players in the pharmaceutical and medical industry is the C.R. Bard, Inc.

C. R. Bard, Inc., (Bard C.R. Inc) recently shortened to Bard, headquartered in their main office in Murray Hill, New Jersey, USA and medical locations around the world, is one of the leaders in developing, manufacturing, and marketing of medical technologies in the following medical fields or specialties: vascular, urology, oncology, and surgical specialties. It creates their dedicated access system, peripheral vascular products, medical supplies and devices in pharmaceuticals. In April 2017, an announcement was done by Bard that it will be acquired by Becton Dickinson.

R. Bard, Inc. Headquarters Address

Traded as	(BCR Stock) NYSE: BCR
Industry focused	Medical specialization
Founded in	1907
Founder	Charles Russell Bard
Headquarters/Based in	New Providence, NJ, USA
Products	Vascular, Oncology, Urology and surgical specialization products

Contacts

Mailing address: 730 Central Avenue, Murray Hill, NJ 07974, USA
Contact number: 908-277-8000
Website: www.crbard.com
Employee email: TS.ServiceDesk@crbard.com
Subsidiaries
1. Bard Medical Div.
2. Davol Inc.
3. Bard Int’l
4. Venetec Int’l, Inc.

Key People/Executives for C. R. Bard, Inc.

Mr. Timothy M. Ring	Chairman and Chief Exec. Officer
Mr. John H. Weiland	Vice Chairman, President and Chief Operating Officer of Bard
Mr. Christopher S. Holland	Chief Financial Officer and Sr. VP
Mr. Timothy P. Collins	Group Pres
Mr. Jim C. Beasley	Group Pres

C. R. Bard, Inc. Profile/Overview

C. R. Bard, Inc. was founded in NYC by a man named Charles R. Bard in 1907. The first venture involved importing the medicine Gomenol, which was used to treat urinary discomfort. Formal incorporation was done in 1923, and three years later, in 1926, Charles let the company be sold to John F. Willits and Edson L. Outwin for $18,000. Under Willits and Outwins, expansion was done into the catheter business, introducing the Foley catheter in 1934 and the America Woven Catheter in 1940.

In 1948, Bard’s yearly sales totalled $1 million for the first time ever, and the company moved its headquarters from New York City to Summit, New Jersey. In 1954, Dr. DeBakey, a scientist from the company, developed the first arterial prosthesis. Three years later the selling Foley catheters that came in sterile packaging was done by Bard for the first time. Furthermore it continued its actions to innovate in the world of catheters, rolling out the Bipolar Temporary Pacing catheter in 1958 and the first latex balloon catheter in 1960. In 1961, expansions were done and began manufacturing products related to cardiology, radiology, and anesthesiology.

IPO was done by Bard in 1963 and was listed on the New York Stock Exchange in the year of 1968. Introduction of variety of new health care products was commenced by the company since that time. Its net sales reached to an amount of over $1 billion. Around the year of 2012, Bard made an acquisition to the company Lutonix.
On April 23, 2017, announcement was done that Becton Dickinson would acquire them for $24 billion.

C. R. Bard, Inc. Products/Capabilities

C. R. Bard, Inc., together with its merged companies and subsidiaries, is dedicated in designing, manufacturing, packaging, distributing, and selling medical, surgical, diagnostic, and patient care devices internationally. The company offers the following:
1. Vascular products, such as, chronic total occlusion catheters, guidewires, percutaneous transluminal angioplasty, cathetersfabrics, meshes, introducers, and accessories
2. Valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters
3. Biopsy devices; and a range of minimally invasive devices for the treatment of peripheral vascular and end-stage renal diseases
4. Urology products, including foley catheters to reduce the rate of urinary tract infections
5. Fecal incontinence products
6. Brachytherapy devices and radioactive seeds for the treatment of prostate cancer
7. Intermittent urinary drainage catheters, and urine monitoring and collection systems
8. Ureteral stents
9. Specialty devices for stone removal procedures
10. Surgical slings and pelvic floor repair products
11. Catheter stabilization devices; and products for therapeutic hypothermia.
12. Oncology products, such as specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters, and enteral feeding devices to treat and manage various cancers, and other diseases and disorders
13. Surgical specialty products comprising implanted grafts and fixation devices for hernia and soft tissue repairs
14. Hemostats and surgical sealants, as well as irrigation, wound drainage, and original equipment manufacturers products.

Boston Scientific Corporation, BSX: Marlborough, Massachusetts, USA

Devices in the medical world are made in quality to its customers and potential ventures. Such companies dedicated to make these are integrated in order to deliver the demands. Mentioning one of the key players in this industry is the Boston Scientific Corporation.

Boston Scientific Corporation (known as Boston Scientific) is a corporate international leader in the development, manufacturing and marketing of medical devices which showcases products in the range of interventional medical specialties, including the following medical disciplines: interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. They are also known in developing diabetes products.

Boston Scientific Corporation Headquarters Address

Traded as	(BSX Stock) NYSE: BSX
Industry focused	Medical devices industry
Founded in	1979
Founder	John Abele, Peter Nicholas, Michael Mahoney and Daniel Brennan
Headquarters/Based in	Marlborough, Massachusetts, USA
Products	Branded medical devices

Contact

Mailing address: 300 Boston Scientific Way, Marlborough, MA 01752, USA
Boston Scientific Japan: Nikko Building,1-14-11 Nishi Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan
Phone number: 508-683-4000
Website: www.bostonscientific.com

Subsidiaries

Guidant
Cameron Health
Symetis SA
Target Therapeutics Inc.
Cardiac Pacemakers, Inc.

Key People/Executives for Boston Scientific Corporation

Mr. Michael F. Mahoney	Chief Exec. Officer, Pres and Director
Mr. Daniel J. Brennan	Chief Financial Officer and Exec. VP
Mr. Timothy A. Pratt	Chief Admin. Officer, Exec. VP, Gen. Counsel and Sec
Mr. Joseph M. Fitzgerald	Exec. VP and Pres of Rhythm Management
Mr. Kevin J. Ballinger	Exec. VP and Pres of Interventional Cardiology

Boston Scientific Corporation Profile/Overview

Forming of the BSC was done on June 29, 1979 as a holding company for a medical products company called Medi-Tech, and to position the company for growth in interventional medicine. IPO was made by the company on May 19, 1992.
Approval to The Taxus Stent was made in 2003 in Europe and other countries and approved in the United States by the FDA in March 2004. It was considered as the second drug-eluting stent approved in the USA.
On April 21, 2006, the company made an acquisition to their longtime competitor Guidant for $27.2 billion. It was then split between BSC and Abbott Laboratories.
Forming of Navilyst Medical was done in February 2008 from Boston Scientific’s Fluid Management and Vascular Access business units.

Boston Scientific Corporation Products/Capabilities

Boston Scientific Corporation is highly dedicated in developing, manufacturing, and marketing medical devices for use in various interventional medical specialties internationally. It operates through three segments:

Cardiovascular
Rhythm Management
MedSurg

The company offers the following products:

Interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease
Other coronary therapy products to treat atherosclerosis
Intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels
Structural heart therapy systems
Stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral arterial disease
Biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors.
Cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms
Implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure
Medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories
Products to diagnose and treat diseases of the pulmonary and gastrointestinal conditions
Devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs
Products to treat urinary stone disease and benign prostatic hyperplasia
Mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices
And spinal cord stimulator systems for the management of chronic pain

(BMRN) BioMarin Pharmaceutical Headquarters

Biotechnological devices and products from are made to the ones who need them in certain businesses and firms. International biotech labs and subsidiaries with their subsequent product pipeline are integrated in order to deliver the needed demands in the market. Mentioning one of the key players in here is the BioMarin Pharmaceutical, Inc.

BioMarin Pharmaceutical Inc. is a company that specialises in the biotech industry. Based in their corporate headquarters in San Rafael, California, it has several locations and offices worldwide. The company’s main business is in enzyme replacement therapies (ERTs). In addition, they were the first biotech company which provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). Also, they were the first proponents to provide therapeutics for phenylketonuria (PKU). The BioMarin pharmaceutical stock is available publicly as well and is open for internship.

BioMarin Pharmaceutical Inc. Headquarters Address

Traded as	(BMRN Stock) NASDAQ: BMRN
Industry focused	Biotechnology
Founded in	1997
Founder	Jean-Jacques Bienaime, Henry J. Fuchs, Dan Spiegelman
Headquarters/Based in	San Rafael, CA, USA
Products	Biotechnological products

Contact

Address Location: 770 Lindaro Street, San Rafael, CA 94901, USA
Contact number: 415-506-6700
Website: http://www.bmrn.com

BioMarin Pharmaceutical Subsidiaries

Prosensa
BioMarin Europe Ltd.
BioMarin International Ltd.
Huxley Pharma.

BioMarin Pharmaceutical Inc. Profile/Overview

In 1997, BioMarin was founded by men named Christopher Starr Ph.D. and Grant W. Denison Jr. with an investment of a $1.5 million from Glyko Biomedical and successfully went public in 1999. Other proponents were MPM Bioventures, Grosvenor Fund and Florian Schönharting. In 2002, BioMarin made an acquisition to Glyko Biomedical.
In 2009, another acquisition was made to Huxley Pharmaceuticals, Inc. (Huxley), which had rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate. In 2010, marketing approval was granted to the company by the European Commission for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate for the treatment of the rare autoimmune disease Lambert-Eaton myasthenic syndrome (LEMS). BioMarin made a product launch of this under the name Firdapse.
In 2010, BioMarin made another acquisition to LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor studied for the treatment of patients with rare, genetically defined cancers.
In 2012, the company made acquisition to Zacharon Pharmaceuticals, a private biotechnology company based in San Diego focused on developing small molecules targeting pathways of glycan metabolism.
In November 2014, the company successfully acquired Prosensa for up to $840 million, the range of treatments for Duchenne Muscular Dystrophy however failed to attain FDA approval and in May 2016 development ceased.

BioMarin Pharmaceutical Inc. Products/Capabilities

BioMarin Pharmaceutical Inc. is dedicated in the successful development and commercialization of pharmaceuticals for serious diseases and medical conditions worldwide. Its commercial products include the following:

Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease
Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease
Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI
Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder.

Clinical trial candidates of BioMarin include:

Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease
pegvaliase, an enzyme substitution therapy for the treatment of PKU
vosoritide, a peptide therapeutic for the treatment of achondroplasia
BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A
BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB.

(BDX) Becton, Dickinson and Company Headquarters

Medical equipment are made to dedicate them to potential customers and firms. Certain creations and acquisitions are being made especially in the health care and their corresponding human resources. Mentioning one of the key players in this industry is the Becton, Dickinson and Company.

Becton, Dickinson and Company (BD) is a MedTech corporation based in the United States that makes and sells medical devices, instrument systems, and other related products. Founded in 1897 and corporate in Franklin Lakes, New Jersey, the company has 50,000 people working in more than 50 locations in countries internationally. In fiscal year ending of September 30, 2009, more than half of BD sales were generated from non-U.S. markets.

Becton, Dickinson and Company Headquarters Address

Traded as	(BDX Stock) NYSE: BDX
Industry focused	Medical equipment
Founded in	1897
Founder	Maxwell Becton, Fairleigh S. Dickinson
Headquarters/Based in	BD HQ, Franklin Lakes, NJ, USA
Products	Medical utility and equipment

Contact

Address location: #1 Becton Drive, Franklin Lakes, NJ 07417, U.S.A.
Phone number: 201-847-6800
Website: http://www.bd.com

Subsidiaries

CareFusion
Accuri Cytometers Inc.
PharMingen
Becton Dickinson A
Becton Dickinson and more.

Key People/Executives for Becton, Dickinson and Company

Mr. Vincent A. Forlenza	Chairman and Chief Executive Officer
Mr. Thomas E. Polen Jr.	President
Mr. Christopher R. Reidy	Chief Financial Officer, Chief Admin. Officer and Executive VP
Mr. Alexandre Conroy	Executive VP and Pres of Europe, EMA and the Americas
Dr. Ellen R. Strahlman M.D., M.H.Sc.	Chief Medical Officer and Executive Vice President of BD R&D

Becton, Dickinson and Company Profile/Overview

Maxwell W. Becton and Fairleigh S. Dickinson were the proponents of the company in 1897, two American businessmen who met on a sales trip. In the same year of first sales, a Luer-all-glass syringe that sold for an amount of $2.50. In 1898, the first patent for a medical product was acquired. In 1899 initial design of logo was created in which was meant to symbolize guaranteed superior quality of the products provided by the company.
In 1948, the next generation of Fairleigh S. Dickinson, Jr. and Henry P. Becton, sons of the founders, led the BD. Their term was a time of rapid development for BD. The company generally grew within the U.S. as well as internationally.
In 1973, another U.S. facility was added by BD—a research center in Durham, North Carolina in Research Triangle Park. It was built to help meet United States Environmental Protection Agency (EPA) requirements, research improved manufacturing and process methods, and develop future innovative technologies.
In 1999, as BD exists for more than a century, it was announced that BD has its new corporate identity. Later then it was shortened to BD.
The notable year of ’06 was to document BD’s growth as the acquisition was done to GeneOhm Sciences—a leader in the development of molecular diagnostic testing for the rapid detection of bacterial organisms and TriPath Imaging—a cancer diagnostics company.

Becton, Dickinson and Company Products/Capabilities

Becton, Dickinson and Company is dedicated to bring medical products internationally. It operates in two segments. They are:

BD Medical – This segment offers products such as syringes, pen needles, and IV sets for diabetes; and intravenous catheters for medication delivery of needles, syringes,; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laproscopic instrumentations; intravenous medication safety and infusion therapy delivery.
BD Life Sciences – The BD Life Sciences segment provides systems for specimen acquisition processes; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; tests for molecular specimen systems for infectious diseases and women’s health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation, and plated media products.

BAX (NYSE): Baxter International Inc. | Headquarters

There is a steadily-increasing demand for equipment in the medical industry. Certain firms are clamouring for more. One of the most recognized companies out there is the Baxter International Inc.

Baxter International Inc. is an international medical company that is listed in the Fortune 500 with locations and stocks around the world. Based on their corporate office in Deerfield US, it mainly focuses on healthcare and products to treat various diseases and inflammations such as hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions. The company had overall sales in 2013 of $16.3 billion, across two businesses such as BioScience and Medical Products.

Baxter International Inc. Headquarters Address

Traded as	(BAX Stock) NYSE: BAX
Industry focused	Medical equipment
Founded in	1931
Founder	Jose E. Almeida, Jay Saccaro
Headquarters/Based in	Deerfield, Illinois, USA
Products	Medical products primarily to treat hemophilia

Contact

Address location: One Baxter Pkwy, Df2-1W Deerfield 60015-4625 United States USA
Phone number/contact information: 224-948-2000
Website: www.baxter.com

Subsidiaries

Gambro
Baxter World Trade Corporation
Baxter India Private Ltd.
Baxter Pharmaceutical Solutions LLC
Baxter Polska Sp. z o.o.
Claris Lifesciences
Baxter Healthcare Ltd. and more.

Key People/Executives for Baxter International Inc.

Mr. José E. Almeida	Chairman, Chief Exec. Officer and Pres
Mr. James K. Saccaro	Chief Financial Officer and Exec. VP
Mr. Brik V. Eyre	Sr. VP and Pres of Americas
Mr. Giuseppe Accogli	Sr. VP and Pres of Global Bus.es
Mr. David P. Scharf	Consultant

Baxter International Inc. Profile/Overview

Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and by patients at home under physician supervision.

Baxter International Inc. Products/Capabilities

Baxter International Inc. provides a portfolio of a wide range of renal and hospital products. The company operates through product pipelines of two segments:

Hospital Products – This segment is responsible for manufacturing intravenous or IV solutions and administration sets, V nutrition products, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, Iparenteral nutrition therapies, infusion pumps, inhalation anesthetics, and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies.
Renal products – The Renal segment is responsible for the provision of products intended to treat end-stage renal disease, irreversible kidney failure, and acute kidney therapies. This segment offers products for various treatment continuums, such as technologies and therapies for peritoneal dialysis, hemodialysis, continuous renal replacement therapy, and additional dialysis services.

(AZN) AstraZeneca Headquarters

Pharmaceutical and biotech companies are dedicated to give quality possible product and service quality to its customers and potential ventures. International medications and pharmaceuticals together with their subsidiaries are integrated in order to deliver the demands. Mentioning one of the key players in the pharmaceutical and biotechnology industry is the AstraZeneca.

AstraZeneca plc is a pharmaceutical and bio-pharmaceutical company based on the nature of an Anglo–Swedish multination. HQ and office locations was transferred to Cambridge, England in 2013, and concentrated its R&D and AstraZeneca pipeline in the following sites: Cambridge; Gaithersburg, Maryland which is the location of MedImmune for bio-pharma work and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs (like diabetes drugs). Consideration as the eighth-largest drug company in the world based on sales revenue was given in the year of 2015.

AstraZeneca Headquarters Address

Traded as	(AZN Stock) LSE: AZN NYSE: AZN
Industry focused	Pharmaceutical and biotechnology
Founded in	April 6, 1999 in Cambridge, England
Founder	Leif Johannson, Pascal Soriot
Headquarters/Based in	Cambridge, England
Products	Branded and generic pharmaceutical products, biotech products

Contact

Address Location: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK
Phone number: 44 20 3749 5000
Website: http://www.astrazeneca.com

Subsidiaries

MedImmune

MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer. Major phase III trials include.

Pipeline
durvalumab (anti-PD-L1)	benralizumab (anti-IL-5R)
tremelimumab (anti-CTLA-4)	tralokinumab (anti-IL-13)
moxetumomab pasudotox (anti-CD22)	anifrolumab (anti-IFN-aR)

Key People/Executives for AstraZeneca

Mr. Pascal Soriot	CEO & Exec. Director
Mr. Marc Dunoyer	CFO & Exec. Director
Ms. Pam P. Cheng	Exec. Vice-Pres of Operations and Information Technology
Mr. Jefrey Pott	Gen. Counsel
Ms. Katarina Ageborg	Chief Compliance Officer

AstraZeneca Profile/Overview

In 1913, Astra AB was initially founded in Södertälje, Sweden, by 400 doctors and apothecaries. In 1993 Demerging of pharmaceuticals businesses and its agrochemicals and specialties businesses was done by the British chemicals company ICI, to form Zeneca Group plc. Eventually in the year of 1999 merging of Astra and Zeneca Group was commenced to form AstraZeneca plc, with its headquarters in London.
In 2002, Irresa, a drug based in Japan, was approved as monotherapy for the condition of non-small cell lung cancer. On 3 January 2004, a management team of ZI Medical was formed by Dr. Robert Nolan, a former director of AstraZeneca.
In July 2017, the company’s CEO Pascal Soriot said that Brexit would not affect its commitment to its current plans in the United Kingdom. However, it had slowed decision making for new investment projects waiting for post-Brexit regulatory regime to settle down.

AstraZeneca Products/Capabilities

AstraZeneca PLC is dedicated to the overall discovery, development, manufacture, and commercialization of prescription medicines for immuno oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases in the international market.

Its marketed products for oncology diseases comprise the following:

Arimidex	Lynparza
Casodex/Cosudex	Nolvadex
Faslodex	Tagrisso
Iressa	Zoladex

Its marketed products for cardiovascular diseases comprise the following:

Atacand1/Atacand HCT/Atacand Plus	Plendil
Brilinta/Brilique	Seloken/Toprol-XL
Crestor	Tenormin
Imdur	Zestril

Its marketed products for metabolic diseases comprise the following:

Bydureon	Onglyza
Byetta	Symlin
Farxiga/Forxiga	Xigduo
Kombiglyze XR	Xigduo XR
Komboglyze

AstraZeneca’s marketed products for respiratory diseases comprise the following:

Accolate	Eklira Genuair/Tudorza Pressair
Bevespi Aerosphere	Oxis Turbuhaler
Bricanyl Respules	Pulmicort Turbuhaler/Pulmicort Flexhaler
Bricanyl Turbuhaler	Pulmicort Respules
Daliresp/Daxas	Symbicort pMDI
Duaklir Genuair	Symbicort Turbuhaler

AstraZeneca’s marketed products for infection diseases comprise the following:

Fluenz Tetra/FluMist Quadrivalent
Synagis

AstraZeneca’s marketed products for neuroscience diseases comprise the following:

Movantik/Moventig
Seroquel IR
Seroquel XR
Vimovo1
Zomig

AstraZeneca’s marketed products for gastrointestinal diseases comprise the following:

Losec/Prilosec
Nexium

Primary care and specialty care physicians through distributors and local representative offices are beign served by AstraZeneca. Their pipeline products include 132 projects, of which 120 are in the clinical phase of development.

Align Technology, Inc. Headquarters Office

Align Technology, Inc. designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment. The Clear Aligner segment consists of its Invisalign System, which includes Invisalign Full, Teen and Assist (Comprehensive Products), Express/Lite (Non-Comprehensive Products) and Vivera Retainers, along with its training and ancillary products for treating malocclusion (Non-Case).

The Scanner segment consists of intra-oral scanning systems and other services available with the intra-oral scanners that provide digital alternatives to the traditional cast models. The Scanner segment includes its iTero scanner and OrthoCAD services.

What is Align Technology, Inc.?

Known for its industry-leading innovative products, Align Technology, Inc. is a leading global health care service company that pioneers in developing technology-rich products not just in its OrthoCad digital services, but also in its Invisalign clear aligners, and iTero Intraoral scanners which help the patients achieve impressive clinical results. Likewise, it helps the dental professionals in delivering plausible and advanced dental options to their patients.

Alexion Pharmaceuticals Headquarters Address

Traded as	NASDAQ: ALGN
Industry focused	Pharmaceutical
Founded in	1992
Founder	Leonard Bell
Headquarters/Based in	New Haven, Connecticut, U.S.
Products	Orthodontics devices

Align Technology, Inc. Contacts

Location: Align Technology Inc 2560 Orchard Pkwy SAN JOSE 95131-1033 United States USA
Phone number number: +1 (408) 738-1500
Fax: +1 (408) 470-1010
Website: www.aligntech.com/

Products and Services

Align Technology, Inc. operates through two segments:

Clear Aligner segment
This prominent segment of Align Tech, Inc. consists of Invisalign System. This includes its comprehensive products such as Invisalign Full, Teen and Assist and non-comprehensive products such as Express/Lite and Vivera Retainers, together with its training and ancillary products for treating malocclusion (Non-Case).
Scanner and Services (Scanner) segment
The Scanner and Services (Scanner) segment of Align Tech consists of intra-oral scanning systems, which provide digital alternatives to the traditional cast models. Among these scanners are its notable iTero scanners and OrthoCAD services.

Align Technology, Inc. Principal Subsidiaries

Align Technology Japan, Inc.
Align Technology, B.V., the Netherlands
Align Technology, Ltd.
Aligntech de Mexico, S. de R.L. de C.V.
Cadent Holdings, Inc.
ICA Ortho Services Pte. Ltd.

ALXN (NASDAQ): Alexion Pharmaceuticals | Headquarters

Alexion Pharmaceuticals, Inc. is a pharmaceutical company that aims to enhance and provide revitalized therapies for patients with life-threatening and rare diseases. It has been its goal to discover and develop medical breakthroughs in biologic therapeutic products that are aimed at treating patients with rare, life-threatening diseases, including cancer and autoimmune disorders, hematologic, kidney and neurologic diseases, and transplant rejections.

Alexion Pharmaceuticals was established in 1992 in New Haven, Connecticut. But it was in 1996 that it became a public company (NASDAQ:ALLXN). In 1998, it began the first in-human clinical trial for eculizumab. And in 2007, Alexion’s eculizumab was sold under the trade name Soliris which was approved by the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for the treatment of patients with paroxysmal nocturnal haemoglobinuri (PNH). Throughout the years, many other breakthroughs and milestones in the field of treating life-threatening diseases were accomplished by Alexion. Also, it was able to acquire Synageva BioPharma, which strengthened its pipeline in establishing a metamorphic franchise with the addition of Kanuma, which was approved as a treatment for patients with hypophosphatasia (HPP)

It was added to the NASDAQ-100 Index in 2011, and only a year after, to the Standard & Poor’s 500 Index. As of 2017, Alexion Pharmaceuticals shares are mostly held by institutional investors (Fidelity Investments, T. Rowe Price, BlackRock and others).

Alexion Pharmaceuticals Headquarters Address

Traded as	NASDAQ: ALXN
Industry focused	Pharmaceutical
Founded in	1992
Founder	Leonard Bell
Headquarters/Based in	New Haven, Connecticut, U.S.
Products	Branded and generic pharmaceutical products

Alexion Contacts

Location: Alexion Pharmaceuticals Inc. 100 College St. NEW HAVEN 06510-3210 United States USA
Phone number number: +1 (203) 272-2596
Fax: +1 (203) 271-8198
Website: www.alxn.com/

Products and Services

Alexion delivers life-changing therapies for patients with life-threatening and rare metabolic disorders: Kanuma (sebelipase alfa) and Strensiq (asfotase alfa). Kanuma is for the treatment of patients with lysosomal acid lipase deficiency (LAL-D), while Strensiq is especially made for patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP)

Alexion developed Eculizumab, sold under the trade name Soliris, which is used in the treatment of two chronic, rare diseases caused by an uncontrolled activation of a branch of the immune system called the complement system. These diseases are paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is likewise approved in the European Union for the treatment of patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.

Key People/Executives for Alexion Pharmaceuticals

David Richard Brennan	Chairman
Dr. Ludwig N. Hantson Ph.D.	Chief Executive Officer & Director
Ms. Julie O’Neill M.B.A.	Executive VP of Global Operations
Dr. David John Anderson M.B.A.	Sr. Adviser to the Chief Executive Officer
Mr. Paul L. Clancy M.B.A	CFO and Chief Executive VP
Daniel A Bazarko CPA	Chief Accounting Officer and Sr. VP

Alexion Pharmaceuticals, Inc. Subsidiaries

Alexion Delaware Holding LLC	Alexion Europe SAS
Alexion Cambridge Corporation	Alexion Pharma France
Alexion Bermuda L.P.	Alexion Pharma Germany GmbH
Alexion Holding B.V.	Alexion Pharma Israel Ltd.
Alexion Pharma International Sarl	Alexion Pharma Italy Sarl
Alexion Pharma Argentina SRL	Alexion Pharma GK
Alexion Pharmaceuticals Australasia PTY LTD	Alexion Pharma Mexico, S. de R.L. de C.V.
Alexion Pharma Belgium Sarl	Alexion Pharma Spain S.L.
Ltda. (doing business as Alexion Latina America)	Alexion Medical Services Sarl
Alexion Pharma Canada Corp.	Alexion İlaç Ticaret Limited Şirketi
Alexion Pharma Colombia SAS	Alexion Pharma UK

Financials

When Soliris, an Alexion-pioneered pharmaceutical product, was first approved in March 2007, the company’s peak annual sales were estimated at $150 million. And by September 2013, quarterly sales of Soliris went up to $400 million. Sales during the first quarter of 2015 were over US$600 million. And as of the first quarter of 2017, Alexion’s total revenues is already worth $870 Million, a 24% increase and 26% volume increase year-over-year
Before Alexion’s announcement of the Synageva BioPharma purchase amounting to $8.4 billion, the company was valued at $34 billion. In the last five years, it saw an increase in stock up to 800% and is currently trading at 46 times estimated earnings. The niche nature of its market as well as the high cost of Soliris, its key revenue driver, enabled the company a high-profit margin.

12 3...11 Page 1 of 11